Former Pennsylvania Congressman Ron Klink authored the following op-ed published on TribLive: October 8, 2020 Never in the history of the modern world has there been such a desperate need for the pharmaceutical industry to be able to save our world and return all of us to a form of normality. Covid-19 is impacting everyone, […]
SMART General President Joseph Sellers, Jr. submitted the following comment on the CMS NPRM noting the potential negative impact of the rule on patient access. Download the comment here. The Honorable Seema VermaAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services Attention: CMS–2482-P Re: Establishing Minimum Standards in Medicaid State Drug Utilization […]
On June 24, 2020, PILMA released the following statement in opposition to price controls contained in the ACA Stabilization legislation. Download the statement here. The coronavirus pandemic has elevated the importance of The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition of unions in the building construction trades and companies in the biopharmaceutical industry. During this […]
The PILMA partners adopted the following statement on May 27, 2020: Download the statement here. For 15 years, labor unions in North America’s Building Trades and companies in the biopharmaceutical industry have developed and advanced a partnership, formalized as the Pharmaceutical Industry Labor-Management Association (PILMA). The biopharmaceutical industry is a vital sector in the United […]
Views ways PILMA’s labor and industry partners are committing to fighting COVID-19. View the biopharmaceutical industry’s principles to beat COVID-19. During the COVID-19 pandemic, the long-standing partnership between the biopharmaceutical industry and highly skilled union construction workers has become ever more important. The PILMA partnership’s mission to create quality union construction jobs, foster innovation, and […]
Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.” PILMA combined DeFrehn’s findings with data from a new report by Berkeley Research Group to extrapolate on the original report and provide insight into which entities in the supply chain are receiving an increasing share of revenue from prescription medicines.